H.C. Wainwright Earlier Maintained Neutral on Nektar Therapeutics, Raised Price Target to $32

H.C. Wainwright earlier maintained Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and raised the price target from $24 to $32.

Benzinga · 11/11/2019 16:48

H.C. Wainwright earlier maintained Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and raised the price target from $24 to $32.